{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:06:19Z","timestamp":1791083179045,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.jiph.2022.02.003","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T13:28:08Z","timestamp":1644931688000},"page":"455-459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Analysis of the clinical application of ceftazidime-avibactam in China"],"prefix":"10.1016","volume":"15","author":[{"given":"Qing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 7","key":"10.1016\/j.jiph.2022.02.003_bib1","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1093\/cid\/ciz830","article-title":"Treatment options for carbapenem-resistant gram-negative bacterial infections","volume":"69","author":"Doi","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2022.02.003_bib2","unstructured":"(CDC), Centers for Disease Control and Prevention. Clinicians: Information about CRE, 2019. [2020\u201312-09] [\u3008https:\/\/www.cdc.gov\/hai\/organisms\/cre\/cre-clinicians.html\u3009]."},{"issue":"5","key":"10.1016\/j.jiph.2022.02.003_bib3","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.mib.2011.07.026","article-title":"Diazabicyclooctanes (DBOs): a potent new class of non-beta-lactam beta-lactamase inhibitors","volume":"14","author":"Coleman","year":"2011","journal-title":"Curr Opin Microbiol"},{"issue":"6","key":"10.1016\/j.jiph.2022.02.003_bib4","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1128\/AAC.02247-12","article-title":"Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and pseudomonas aeruginosa AmpC beta-lactamases","volume":"57","author":"Lahiri","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.jiph.2022.02.003_bib5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by klebsiella pneumoniae carbapenemase-producing K. pneumoniae","volume":"68","author":"Tumbarello","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.jiph.2022.02.003_bib6","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant enterobacteriaceae infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2022.02.003_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1128\/AAC.00449-17","article-title":"Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant enterobacteriaceae infections","volume":"61","author":"King","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2022.02.003_bib8","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jgar.2020.10.023","article-title":"Clinical characteristics and outcomes of patients with multidrug-resistant Gram-negative bacterial infections treated with ceftazidime\/avibactam","volume":"23","author":"Kuang","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jiph.2022.02.003_bib9","unstructured":"Fan HW, Wang HL, Zhou BT, et al. The Sanford Guide to Antimicrobial Therapy 2018 (Tranlated version) (48thEdition) [M]."},{"issue":"5","key":"10.1016\/j.jiph.2022.02.003_bib10","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jiph.2022.02.003_bib11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1086\/649554","article-title":"Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the surgical infection society and the infectious diseases society of America","volume":"50","author":"Solomkin","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jiph.2022.02.003_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/599376","article-title":"Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the infectious diseases society of America","volume":"49","author":"Mermel","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jiph.2022.02.003_bib13","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1086\/650482","article-title":"Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the infectious diseases society of America","volume":"50","author":"Hooton","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.jiph.2022.02.003_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106075","article-title":"Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort","volume":"56","author":"Cast\u00f3n","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.jiph.2022.02.003_bib15","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/cc2872","article-title":"Acute renal failure \u2013\u00a0definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the acute dialysis quality initiative (ADQI) group","volume":"8","author":"Bellomo","year":"2004","journal-title":"Crit Care"},{"key":"10.1016\/j.jiph.2022.02.003_bib16","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1128\/CMR.00079-17","article-title":"Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing enterobacteriaceae","volume":"31","author":"Rodr\u00edguez-Ba\u00f1o","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jiph.2022.02.003_bib17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1128\/AAC.02187-18","article-title":"Dose selection and validation for ceftazidime-avibactam in adults with complicated intra-abdominal infections, complicated urinary tract infections, and nosocomial pneumonia","volume":"63","author":"Das","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2022.02.003_bib18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/antibiotics9070388","article-title":"Ceftazidime-avibactam combination therapy compared to ceftazidime-avibactam monotherapy for the treatment of severe infections due to carbapenem-resistant pathogens: a systematic review and network meta-analysis","volume":"9","author":"Fiore","year":"2020","journal-title":"Antibiotics"},{"issue":"6","key":"10.1016\/j.jiph.2022.02.003_bib19","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ijantimicag.2019.08.025","article-title":"Efficacy of ceftazidime\/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: a meta-analysis","volume":"54","author":"Onorato","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiph.2022.02.003_bib20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/nyas.12537","article-title":"Carbapenem\u2010resistant enterobacteriaceae: biology, epidemiology, and management","volume":"1323","author":"Temkin","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jiph.2022.02.003_bib21","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/jac\/dkm356","article-title":"Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case\u2013control study","volume":"60","author":"Falagas","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2022.02.003_bib22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/cid\/cir202","article-title":"Carbapenem-resistant enterobacteriaceae: epidemiology and prevention","volume":"53","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"suppl_1","key":"10.1016\/j.jiph.2022.02.003_bib23","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1093\/infdis\/jiw282","article-title":"The epidemiology of carbapenem-resistant enterobacteriaceae: the impact and evolution of a global menace","volume":"215","author":"Logan","year":"2017","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.jiph.2022.02.003_bib24","doi-asserted-by":"crossref","DOI":"10.1099\/jmm.0.001286","article-title":"Frequency of and risk factors for carbapenem-resistant enterobacteriaceae","volume":"70","author":"Barber","year":"2021","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.jiph.2022.02.003_bib25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1128\/AAC.02497-17","article-title":"Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant enterobacteriaceae infections","volume":"62","author":"Shields","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2022.02.003_bib26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1128\/AAC.01964-16","article-title":"Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms","volume":"61","author":"Temkin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2022.02.003_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciab176","article-title":"Ceftazidime-avibactam use for KPC-Kp infections: a retrospective observational multicenter study","volume":"73","author":"Tumbarello","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034122000375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034122000375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:12:09Z","timestamp":1761750729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034122000375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1876034122000375"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2022.02.003","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of the clinical application of ceftazidime-avibactam in China","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2022.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}]}}